South Africa Cancer Immunotherapy Market Size & Outlook
South Africa cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
South Africa cancer immunotherapy market highlights
- The South Africa cancer immunotherapy market generated a revenue of USD 409.6 million in 2023 and is expected to reach USD 684.2 million by 2030.
- The South Africa market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 409.6 million |
| Market revenue in 2030 | USD 684.2 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.3% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Kuwait is the fastest growing regional market in Middle East & Africa and is projected to reach USD 103.7 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 66.55% in 2023. Horizon Databook has segmented the South Africa cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Advancements in cancer immunotherapy indicate a possibility of significantly lowering the cancer burden in South Africa. Among all cancer type, immunotherapy has worked best in the treatment of advanced melanoma and lung cancer. Nearly, 1 out of every 3 diagnosed cancer is melanoma.
Furthermore, it is estimated that 70% of all cancer cases will occur in developing countries by 2030. The alarming rise in cancer incidence rates has provoked global collaboration on cancer drugs and other therapies.
The introduction of immunotherapy has aided in saving 1 out of every 4 melanoma patients. Although the usage of immunotherapy is minimal as compared to chemotherapy, radiotherapy, and surgery, we anticipate immunotherapy to emerge as the leading treatment strategy for cancer over the next few years.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Africa cancer immunotherapy market size, by product, 2018-2030 (US$M)
South Africa Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
